27th Interphex Week 2025 Tokyo Exhibition

From the medical field to cosmetics and health food sectors, we provide optimal solutions with abundant experience and high engineering technology.

- Over 40 years of experience in the pharmaceutical factory construction field with more than 200 achievements - Leveraging the experience gained from specializing in user-oriented engineering, we support the establishment of optimal production facilities, from the development and production of pharmaceuticals to the maintenance of factories and equipment. <Pharmaceuticals> Active pharmaceutical ingredients, intermediates, formulations, injectables, biological products, nucleic acids, biopharmaceuticals, regenerative medicine <Cosmetics> Medicinal cosmetics, basic cosmetics, sun care, makeup, hair care cosmetics <Health Foods> Supplements, beverages, etc. For more details on Mitsubishi Chemical Engineering's medical engineering, please refer to the related links.

• Pharmaceutical factory equipment
• Pharmaceutical related factory equipment
• Plant Design

Streamlining the production of solid dosage forms and integrating factory functions into a one-stop system.

We will build an optimal continuous production system for our customers based on the continuous production process construction technology cultivated over many years through chemical plants and our extensive track record in the manufacturing of active pharmaceutical ingredients, cosmetics, and food. 【Features】 ■ Constructing an optimal continuous production system from the customer's perspective ■ Contributing to load reduction and achieving stable quality and stable supply through PSE & PAT ■ The inspection and sorting device "iSorter," which supports the development of quality control strategies, can automatically sort off-spec products ■ Planning a quality control strategy suitable for the manufacturing process and building an optimal information control system 【Benefits of Implementing Continuous Production (Examples)】 ■ Stable quality supply ・ Real-time monitoring enables reliable manufacturing ■ Flexibility in production volume ・ Adjusting production volume by changing operating hours ・ Flexibly responding to fluctuations in demand ■ Space-saving manufacturing equipment ・ Reduction and space-saving of equipment ・ Reduction in energy consumption

• Other production management systems
• Other pharmaceutical factory equipment and parts
• Pharmaceutical related factory equipment

Containment systems in the production of highly pharmacologically active substances.

In recent years, the expansion of the market for anticancer drugs and other pharmaceuticals has led to an increase in manufacturing facilities for highly pharmacologically active drugs. In such manufacturing facilities, containment technologies are required to prevent the dispersion and suspension of highly pharmacologically active powders in response to cross-contamination, health hazards, and environmental pollution. Our company will build the optimal containment system tailored to the grade of containment required for manufacturing facilities. 【Features】 ■ Ensures a reliable level of safety and health management for workers through exposure management ■ Guarantees product quality by preventing cross-contamination ■ Optimal system based on equipment shape and workability ■ Comprehensive construction of the entire manufacturing facility, including primary and secondary containment 【Examples of containment equipment using isolators (primary containment)】 ■ Charging into the reactor ■ Extraction from the filter dryer ■ Extraction from the filter

• Other pharmaceutical factory equipment and parts
• Other pharmaceutical-related factory equipment and parts
• Pharmaceutical related factory equipment

Gather, know, and lead to the future! A partner for stabilizing quality that realizes "productivity improvement" and "strengthening on-site capabilities."

"VectorScope" visualizes various manufacturing-related data accumulated in the production site, such as temperature, pressure, and raw material composition, using a unique synthetic vector method to create a new indicator called "manufacturing status." By exploring the relationship between this manufacturing status and product quality, we aim to achieve "productivity improvement" and "skill enhancement of technical staff" in collaboration with our customers, contributing to further stable growth through "DX." This method has a proven track record across various fields and processes, from chemicals and resins to pharmaceuticals and food. [Features] - Anyone can engage in big data analysis without knowledge of statistical analysis. - Visualization of manufacturing experience enables understanding and sharing of the manufacturing site's capabilities (Best Practices). - Deepening, inheriting, and expanding technology through a spiral-up of manufacturing improvements. - Achieving productivity improvement in your factory through "visualization of manufacturing experience." - Realizing speedy and effective continuous manufacturing quality improvement activities. [Commitment to DX] - Transitioning to data-driven on-site communication. - Deepening manufacturing technology and inheriting skills using manufacturing performance data. - Early detection and improvement of issues through continuous visualization of manufacturing data.

• Other analyses
• Production Management System
• Business Intelligence and Data Analysis

Although I have heard that verification efficiency at the RTL stage improves with verification methodologies using SystemVerilog such as UVM, many designers may not fully understand what can be done with SystemVerilog and how to use it. In this seminar, we will introduce the basic functions and usefulness of SystemVerilog verification using a sample design. 1. Design Overview 2. UART Test Environment 3. Assertions (SVA & PSL) 4. Functional Coverage 5. Random Test Bench 6. DPI-C

The RTCA/DO-254 guidance recommends that applicants define and implement HDL coding standards. This work begins with a planning process that includes the definition of the standard, how it will be implemented, and, if the process is automated, the evaluation methods for tools or results. A key issue is that the guidance does not have clearly defined formal standards, leading to questions about how to conduct a detailed review of HDL code. In this webinar, we will demonstrate the use of ALINT-PRO to enforce coding standards and highlight the benefits of streamlining the overall design review to meet the objectives of DO-254.

[Speaker] Takahiro Tachikawa, President of International University and Professor at the Graduate School of International Management [Key Lecture Content] In February of this year, the 7th Energy Basic Plan was approved by the Cabinet. What is the essence of this plan that the media and others do not convey? How will this plan impact the development and social implementation of hydrogen, ammonia, and next-generation fuels (synthetic methane, synthetic liquid fuels, green LP gas, etc.)? This lecture will delve into these points. In particular, it will focus on the content of the risk scenario, which is viewed as the main scenario among stakeholders in the energy industry, and the newly defined role of natural gas as an "important energy source even after achieving carbon neutrality." [Lecture Items] 1. The 7th Energy Basic Plan 2. Hydrogen 3. Ammonia 4. Synthetic Fuels 5. Risk Scenario 6. Natural Gas Shift 7. Q&A / Business Card Exchange

[Lecturer] Professor Shiro Kawabata, Faculty of Science and Technology, Hosei University [Key Lecture Content] Prime Minister Ishiba has positioned 2025 as the inaugural year for the industrialization of quantum technology and has indicated a policy to strengthen support for the industrialization of quantum technology. Additionally, at the G7 Summit held in Canada in June 2025, a joint statement titled "Joint Statement on the Future of Quantum Technology," focusing on quantum technology centered around quantum computers, was adopted. Quantum computers are computers that utilize principles of quantum mechanics, such as superposition and quantum entanglement, for information processing. By using quantum computers, it becomes possible to solve several mathematical problems, such as factorization, machine learning, quantum chemistry calculations, finance, and linear simultaneous equations, exponentially faster compared to classical computers. As a result, major global corporations and startups are globally expanding their development and business in quantum computer hardware and software. This seminar will introduce the basics of quantum computers, the latest research and development trends, business trends, technical challenges, and future prospects.

[Speaker] Shintaro Kobayashi, Group Manager, ICT and Content Industry Consulting Department, Nomura Research Institute, Ltd. [Key Lecture Content] The Personal Information Protection Law is undergoing fundamental changes to promote AI development. The Personal Information Protection Commission has proposed a shift towards a risk-based system where companies voluntarily address risks. A key feature of this new system is the establishment of a framework that allows the use of personal information for AI development without the need for individual consent. In this lecture, based on the policy of legal reform, we will carefully explain the points for advancing data utilization by leveraging the legal benefits of the new system, as well as how to establish privacy governance that should drive these efforts, incorporating specific initiatives and examples of solutions. [Lecture Items] 1. Trends in the amendment of the Personal Information Protection Law 2. Practical methods for utilizing personal information without individual consent 3. PETs for safely utilizing AI 4. Achieving governance efficiency and sophistication through AI 5. Q&A / Business card exchange